BioSpace News Archive

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced business updates and financial results for the third quarter ended September 30, 2022.

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the third quarter 2022, recent business highlights, and key upcoming catalysts.

Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced operating results for the three months ended September 30, 2022.

Baudax Bio, Inc. reported financial results for the three and nine months ended September 30, 2022, updated the status of the neuromuscular blocking agent development program, provided key metrics around the ongoing commercialization of ANJESO injection, and provided an overview of other corporate and financial developments.

Electromed, Inc., a leader in innovative airway clearance technologies, announced financial results for the three months ended September 30, 2022.

Senseonics Holdings, Inc., a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring systems for people with diabetes, reported financial results for the quarter ended September 30, 2022.

Masimo announced its financial results for the third quarter of 2022, ended October 1, 2022.

Revance Therapeutics, Inc., reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the third quarter of 2022 and provided key business updates across the company’s clinical-stage pipeline of novel NMDA receptor modulators.

Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced that the Adrian Adams, Chairman and Chief Executive Officer, will participate in a fireside chat at the Guggenheim 4th Annual Immunology and Neurology Day on Tuesday, November 15, 2022 at 1:00 p.m. ET in New York, NY.